Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.2217/imt.15.77

http://scihub22266oqcxt.onion/10.2217/imt.15.77
suck pdf from google scholar
C4976846!4976846 !26370838
unlimited free pdf from europmc26370838
    free
PDF from PMC    free
html from PMC    free

Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26370838 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215

suck abstract from ncbi


Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26370838 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117
pmid26370838
      Immunotherapy 2015 ; 7 (11 ): 1187-99
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Targeting B-cell maturation antigen in multiple myeloma #MMPMID26370838
  • Tai YT ; Anderson KC
  • Immunotherapy 2015[]; 7 (11 ): 1187-99 PMID26370838 show ga
  • Novel effective immunotherapies are needed for patients with multiple myeloma (MM), since disease recurrence remains a major obstacle. B-cell maturation antigen (BCMA), a cell surface protein universally expressed on malignant plasma cells , has emerged as a very selective antigen to be targeted in novel treatments for MM. We here first review BCMA-related biology, and then highlight the recent clinical development of a novel afucosylated anti-BCMA monoclonal antibody conjugated with monomethyl auristatin F via noncleavable linker (GSK2857916). Chimeric antigen receptor-expressing T cells targeting BCMA may also induce specific and durable anti-MM responses by patients' own effector cells. Clinical trials testing these two approaches (NCT02064387, NCT02215967) are currently ongoing in relapsed and refractory MM patients.
  • |*Immunotherapy [MESH]
  • |Animals [MESH]
  • |Antibodies, Monoclonal/chemistry/*therapeutic use [MESH]
  • |Antigens, Neoplasm/immunology/*metabolism [MESH]
  • |B-Cell Maturation Antigen/immunology/*metabolism [MESH]
  • |Clinical Trials as Topic [MESH]
  • |Humans [MESH]
  • |Molecular Targeted Therapy [MESH]
  • |Multiple Myeloma/immunology/*therapy [MESH]
  • |Oligopeptides/chemistry [MESH]
  • |Protein Engineering [MESH]
  • |Receptors, Antigen, T-Cell/genetics [MESH]
  • |Recombinant Fusion Proteins/genetics [MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box